- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
Patent holdings for IPC class C07D 231/02
Total number of patents in this class: 81
10-year publication summary
|
4
|
2
|
5
|
6
|
6
|
7
|
5
|
6
|
6
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2183 |
5 |
| Novartis AG | 10160 |
4 |
| Celgene Corporation | 1408 |
4 |
| National Institute of Biological Sciences, Beijing | 102 |
3 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3371 |
3 |
| Northwestern University | 3593 |
2 |
| FMC Corporation | 817 |
2 |
| Fox Chase Chemical Diversity Center, Inc. | 15 |
2 |
| Verseon Corporation | 9 |
2 |
| Virginia Commonwealth University | 671 |
2 |
| Rezolute, Inc. | 35 |
2 |
| Praxis Precision Medicines, Inc. | 238 |
2 |
| Nuvalent, Inc. | 91 |
2 |
| Merck Sharp & Dohme LLC | 3734 |
2 |
| Genentech, Inc. | 4161 |
1 |
| Janssen Pharmaceutica N.V. | 3129 |
1 |
| Merck Patent GmbH | 5761 |
1 |
| The Board of Trustees of the Leland Stanford Junior University | 6734 |
1 |
| The Regents of the University of Michigan | 5081 |
1 |
| Vertex Pharmaceuticals Incorporated | 1578 |
1 |
| Other owners | 38 |